CANFNYSEPharmaceutical PreparationsFiscal year ends December 31
Can-Fite BioPharma Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$1.89+0.13 (+7.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1.9%
0M of 3M shares
Institutional holders
8
0 new, 6 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CANF | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 32,533 | 1.24% | $96.62K | −1,617 | 0.00% |
| Rhumbline Advisers | 17,433 | 0.67% | $51.77K | −3,475 | 0.00% |
| Fifth Third Bancorp | 150 | 0.01% | $446 | – | 0.00% |
| Wells Fargo & Company/Mn | 59 | 0.00% | $175 | −66 | 0.00% |
| Activest Wealth Management | 10 | 0.00% | $30 | – | 0.00% |
| Avion Wealth | 5 | 0.00% | $0 | – | 0.00% |
| Morgan Stanley | 1 | 0.00% | $3 | – | 0.00% |
| TD Waterhouse Canada Inc. | 1 | 0.00% | $4 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 0M | 1.9% | 0 / 0 | 3 / 6 | 0M | 0M |
| Q1 2026 | 14 | 0M | 5.3% | 14 / 0 | 0 / 1 | 0M | 0M |
| Q4 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CANF | Value | % of fund | As of |
|---|---|---|---|---|---|
| Blackstone Alternative Multi-Strategy Fund | 50 | 0.00% | $149 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Pnina Fishman | Chief Scientific Officer, Director | 88 | 0.00% | Jun 8, 2026 |
| Motti Farbstein | CEO, CFO and COO | – | – | Jun 8, 2026 |
| Sari Fishman | VP Business Development | – | – | Mar 18, 2026 |
| Ilan Tamir | Director | – | – | Apr 23, 2026 |
| Guy Regev | Director | 8 | 0.00% | Apr 6, 2026 |
| Abraham Sartani | Director | – | – | Mar 18, 2026 |
| Yoseph Bornstein | Director | – | – | Mar 18, 2026 |